Scientific Sessions 2025  /  From Bench to Bedside: Unraveling Mechanisms of Cardiovascular Disease in CKD  /  Tocilizumab: Potential Protective Effects Against Acute Kidney Injury and Cardiorenal Dysfunction
Logo

American Heart Association

  46
  0

Final ID: Su1030

Tocilizumab: Potential Protective Effects Against Acute Kidney Injury and Cardiorenal Dysfunction

Abstract Body (Do not enter title and authors here): Cardiovascular diseases can lead to acute kidney injury (AKI) through cardiorenal syndrome by reducing renal blood flow and increasing venous congestion. According to the Kidney Disease: Improving Global Outcomes (KDIGO, 2012), during hospitalization, 1 in 5 adults developed acute kidney injury (AKI), caused by renal insults that lead to oxidative stress. Such events can trigger changes in the mitochondrial respiratory chain, inducing apoptosis, structural abnormalities in cells and their organelles, and even mitochondrial DNA instability. In this context, Tocilizumab is a monoclonal antibody that inhibits interleukin-6 (IL-6). Hipotesis: To evaluate the effect of Tocilizumab on renal function and oxidative profile in rats with ischemia-reperfusion-induced acute kidney injury (IR-AKI). Methodology: male adult Wistar rats, divided into 4 groups (N=7): Control (SHAM); TCZ (Tocilizumab; 4 mg/kg, i.p.; single dose); Ischemia and Reperfusion (I/R; clamping of the renal pedicles); TCZ+I/R (Tocilizumab treatment followed by ischemia). Renal function was assessed by serum and urinary creatinine levels and inulin clearance, as well as the oxidative profile. This study was approved by the Animal Use Ethics Committee (CEUA), under protocol number 2014/2023. Results: The analyses showed a significant reduction in serum creatinine levels and an increase in inulin clearance in the TCZ+I/R group compared to the I/R group. Regarding the oxidative profile, analyzed through the FOX and TBARS methods, an increase in urinary peroxides was observed in the TCZ group compared to the SHAM group, while a significant reduction was noted in the TCZ+I/R group compared to the I/R group. The urinary nitrate test revealed lower expression in the TCZ+I/R group. Similarly, the thiol test demonstrated reduced antioxidant activity in the TCZ+I/R group compared to the treated control groups. Discussion: Tocilizumab (TCZ) is an important IL-6 inhibitor, since IL-6 plays a key role in renal inflammatory responses, both in acute and chronic processes. In this study, the use of this drug proved to be promising for the prevention of IR-AKI, by inhibiting a key mediator involved in the amplification of inflammation. Conclusion: In conclusion, the Tocilizumab demonstrated a renoprotective effect, improving renal function and reducing oxidative activity. It presents itself as a potential adjuvant therapy in conditions with a risk of renal ischemia, such as kidney transplantation.
  • Vattimo, Maria De Fatima  ( University of Sao Paulo , Sao Paulo , Brazil )
  • Tsuchiya, Julia  ( University of Sao Paulo , Sao Paulo , Brazil )
  • Veloso Gusmao Silva, Juliana  ( University of Sao Paulo , Sao Paulo , Brazil )
  • Gomes Alves, Mykelly  ( University of Sao Paulo , Sao Paulo , Brazil )
  • Oliveira Silva, Eloiza  ( University os Sao Paulo , Sao Paulo , Brazil )
  • Gonzaga, Maria JosÉ Dias  ( University of Sao Paulo , Sao Paulo , Brazil )
    • Author Disclosures:
    Maria de Fatima Vattimo: DO NOT have relevant financial relationships | Julia Tsuchiya: DO NOT have relevant financial relationships | Juliana veloso gusmao silva: DO NOT have relevant financial relationships | Mykelly Gomes Alves: No Answer | Eloiza Oliveira Silva: DO NOT have relevant financial relationships | MARIA JOSÉ DIAS GONZAGA: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

From Bench to Bedside: Unraveling Mechanisms of Cardiovascular Disease in CKD

Sunday, 11/09/2025 , 03:15PM - 04:15PM

Abstract Poster Board Session

More abstracts on this topic:
Acculturation and Cardiovascular-Kidney-Metabolic Syndrome: a Study of Immigrant Adults From the National Health and Nutrition Examination Survey

Chakrabarti Amit, Le Austin, Elfassy Tali, Yang Eugene

BXOS110 for Acute Ischemic Stroke Treatment (BEST): A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial

Ding Yarong, Li Shuya, Wang Zhe, Li Zixiao, Meng Xia, Zhao Xingquan, Wang Yongjun, Li Zixiao

More abstracts from these authors:
Cardiovascular and Renal Effects of Physical Training in Male Rats Under Tenofovir Disoproxil Fumarate Treatment

Vattimo Maria De Fatima, Veloso Gusmao Silva Juliana, Victoria Carla, Oliveira Silva Eloiza, Gomes Alves Mykelly, Garcia Villalba Jessica, Tsuchiya Julia, Polastri Thatiane, Coelho Filipe Utuari De Andrade

Dual Therapy with Semaglutide and Physical Training Lowers Cardiorenal Burden in Experimental DKD and renal cells

Vattimo Maria De Fatima, Oliveira Silva Eloiza, Garcia Villalba Jessica, Goncalves Maikol Lucas, Veloso Gusmao Silva Juliana, Gomes Alves Mykelly, Victoria Carla, Gonzaga Maria JosÉ Dias, Polastri Thatiane

4370479_File000000.jpg
4370479_File000000.jpg
4370479_File000001.jpg
4370479_File000001.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available